Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  2. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.

  3. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  4. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  5. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  6. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  7. Drug

    AstraZeneca COVID-19 Vaccine

    go.drugbank.com/drugs/DB15656
    ApprovedInvestigational

    [L12672] The University of Oxford struck a development and distribution deal with AstraZeneca in May 2020[L32659] which paved the way for the vaccine's subsequent approval and usage in dozens of regions … [L32674] A phase I/II single-blinded, randomized, placebo-controlled trial to investigate the safety, efficacy, and immunogenicity of the vaccine began in April 2020 with an expected completion date

  8. Drug

    Citrulline

    go.drugbank.com/drugs/DB00155
    InvestigationalNutraceutical

    Citrulline is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. … It is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.

    Synonyms: N(delta)-Carbamylornithine, N(5)-(Aminocarbonyl)-L-ornithine
  9. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

  10. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia